February

February

Herpes Virus Opens “Whole New World of Treatment” for Brain Cancer

By Admin at 29 Feb 2016

Glioblastoma is the most common type of brain cancer. It’s often aggressive and has a median survival time of under 15 months on average. Researchers are offering new hope for treatment in this area using an unlikely “weapon” – herpes virus.

0 comments posted

New Study Helps Solve Mysteries About How Tumors Form

By Admin at 24 Feb 2016

There are many mysteries surrounding how and why cancerous tumors form. Although it’s been suggested that tumors are the result of cells sticking together, new research found that the process is not nearly as passive. Instead, tumor cells “actively recruit” other cells in a very determined, purposeful process.

0 comments posted

7 Natural Supplements Cancer Patients Should Avoid

By Admin at 17 Feb 2016

Dietary supplements are incredibly popular among cancer patients. In one study of more than 200 cancer patients receiving treatment, 73 percent had used some form of supplement during the past 30 days.

0 comments posted

Chemotherapy-Related Nerve Damage is Common Among Cancer Survivors

By Admin at 16 Feb 2016

In research presented at the American Society of Clinical Oncology (ASCO) meeting in San Francisco, California, it was revealed just how common chemotherapy-related nerve damage actually is, even years after treatment has ended.

0 comments posted

3-D Model of Heparanase, a Key Anti-Cancer Target, Developed

By Admin at 15 Feb 2016

Researchers from Griffith University's Institute for Glycomics have succeeded in a world first. They’ve used X-ray crystallography to create a 3-D image of a bacterial heparanase, a protein involved in cancer spread.

0 comments posted

    Categories

    Archive

    2018 2017 2016 2015
    99 cents of every dollar received directly funds cancer clinical trials

    57

    Current Gateway-funded clinical trials

    150+

    Clinical trials funded at leading institutions worldwide

    $16.56

    Funds one patient for one day at a Gateway-funded clinical trial

     
     

    Mission Partners